68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

April 1, 2027

Conditions

Liver CancerHepatocellular CarcinomaMetastatic Liver Cancer

Interventions

DRUG

Lu-PSMA-617

Given IV

Trial Locations (1)

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland